Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Ibrutinib and venetoclax: a powerful combination in frontline and relapsed CLL

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Nitin Jain, MD, from the MD Anderson Cancer Center, Houston, TX, discusses his trial (NCT02756897) examining the synergistic effect of venetoclax and ibrutinib in high risk chronic lymphocytic leukemia (CLL). Current data from this study show impressive rates of minimal residual disease negativity, demonstrating the potency of this combination and the great potential of the therapy.